Human CD20 Antibody - Obinutuzumab Biosimilar

CD20 antibody - Obinutuzumab biosimilar - CAS# 949142-50-1

Anti-hCD20-Ga-hIgG1fut is a research biosimilar antibody to the clinical antibody Obinutuzumab. Obinutuzumab is a type II (second generation) non-fucosylated, fully humanized IgG1 monoclonal antibody with improved therapeutic efficacy compared with previously developed type I (first generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab (Afutuzumab, GA101) targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes. Obinutuzumab has been approved by the FDA to treat chronic lymphocytic leukemia [1-3].

Anti-hCD20-Ga-hIgG1fut features the variable region of Obinutuzumab and a non-fucosylated (fut), human IgG1 constant region for very high effector functions. For applications requiring high Fc effector activity, InvivoGen also offers Anti-hCD20-Ga-hIgG1, a Obinutuzumab-based research antibody.

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect™ assay

This antibody is suitable for effector function analysis, screening assays, and cytotoxic bio-assays. It can be used in ADCC effector activity assays in combination with Jurkat-Lucia™ NFAT-CD16 effector cells and Raji target cells.

InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc region.

References:

1. Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
2. Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306. 4. Mizushima T., 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 16(11): 1071–1080.